nebulized glutathione for parkinson& 39 The system in Parkinson's disease and its progression Closing the loop for patients

Gouaze V, Andrieu-Abadie N, Cuvillier O, Malagarie-Cazenave S, Frisach MF, Mirault ME et al

J.LotzeM

To create sustained-release microneedles, the biodegradable tolerogenic nanoparticles (tNPs) were synthesized and loaded with the immunomodulator rapamycin and the model allergen ovalbumin (OVA)

Remarkably, ~5090% reduction of L68Q-hCC staining was observed in five of the treated carriers suggesting that L68Q-hCC is a clinical target for reducing agents

doi: 10.4103/0976-0105.177703

These profiles are supported by biochemical and metabolic findings, but they are not recognized as formal clinical subtypes, nor are they used to stratify participants in clinical trials